Antigen-binding molecules that bind CD38 and/or CD28, and uses thereof

ChangeBridge: Patent Grants - Peptides (C07K)

Published March 31st, 2026

Detected March 31st, 2026

Summary

USPTO granted Regeneron Pharmaceuticals Patent No. US12590168B2 covering CD38/CD28 bispecific antibodies designed to activate T-cells and inhibit tumor growth. The patent includes 35 claims and covers methods for treating cancers including multiple myeloma, lymphoma, and leukemia using bispecific antigen-binding molecules.

View original document View source feed page

What changed

The USPTO issued Patent US12590168B2 to Regeneron Pharmaceuticals, Inc. for novel anti-CD38 and anti-CD28 bispecific antibodies (bsAbs) that function as costimulatory agents to activate T-cells via binding CD80 and/or CD86. The patent covers methods of inhibiting tumor growth expressing CD38 and treating diseases where upregulated CD38-targeted immune response is therapeutically beneficial. The patent includes 35 claims across CPC classifications C07K 16/2818, C07K 16/2878, and related composition categories.

Pharmaceutical companies developing bispecific antibody therapeutics targeting CD38 or CD28 pathways should review this patent to assess freedom-to-operate considerations. The patent may impact R&D programs, licensing negotiations, and competitive landscape analysis for multiple myeloma, lymphoma, and leukemia treatments. No immediate compliance actions are required as patent grants do not impose new regulatory obligations.

What to do next

Review patent claims for freedom-to-operate analysis on CD38/CD28 bispecific antibody programs
Assess potential licensing needs with Regeneron for therapeutic development
Update IP portfolio monitoring to include US12590168B2

Source document (simplified)

← USPTO Patent Grants

Antigen-binding molecules that bind CD38 and/or CD28, and uses thereof

Grant US12590168B2 Kind: B2 Mar 31, 2026

Assignee

Regeneron Pharmaceuticals, Inc.

Inventors

David DiLillo, Aynur Hermann, Jessica Kirshner, Kara Olson, Olga Sineshchekova, Eric Smith, Erica Ullman

Abstract

CD38 is expressed on malignant plasma cells. CD28 is a costimulatory molecule required for T-cell activation and survival. Provided herein are novel anti-CD38 antibodies, anti-CD28 antibodies, and bispecific antibodies (bsAbs) that bind to both CD38 and CD28 and act as costimulatory agents to activate T cells via binding CD80 and/or CD86. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing CD38. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced CD38-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of various cancers, including multiple myeloma, lymphoma, and leukemia.